Legal status · Australia
Is BI 1820237 legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. BI 1820237 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
BI 1820237 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 2 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the BI 1820237 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
BI 1820237 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What BI 1820237 is
A first-in-human study in 95 men that found the thing combination therapy has to worry about: its effect on gastric emptying was additive with liraglutide, which is where the nausea comes from.
Boehringer Ingelheim's entry into the same pathway as the PYY analogue, aimed at the same problem: GLP-1 drugs cause gastrointestinal side effects and some people do not respond to them, so a second satiety receptor is worth targeting. The phase 1 result is mostly a tolerability story, and a specific one.
Mechanism: A peptidic agonist at neuropeptide Y receptor type 2, the same receptor PYY(3-36) acts through. Y2 is presynaptic and inhibitory on hypothalamic neuropeptide Y neurons, so agonising it reduces appetite drive.
Regulatory history: Investigational. Phase 1 published, plus a combination study with survodutide.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for BI 1820237 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
BI 1820237 in other countries
Frequently asked questions
Is BI 1820237 legal in Australia?
No. BI 1820237 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Can I buy BI 1820237 in Australia?
No approved product exists to buy. In Australia BI 1820237 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is BI 1820237 TGA approved?
No. In Australia BI 1820237 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Investigational. Phase 1 published, plus a combination study with survodutide.. On the evidence, 2 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for BI 1820237 live on its compound profile.
BI 1820237 profileThis page is general information about the regulatory status of BI 1820237 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.